A little more in depth than the asx ann previously made, taken...

A little more in depth than the asx ann previously made, taken from GICC LC website




Setting Up Of Singapore Joint Venture To Manufacture GICC LLC Products and Promote ServicesFor Markets Outside The United States

Global Infection Control Consultants (“GICC”) LLC is pleased to announce a joint venture with our long-term partner, Holista Colltech Limited (“HCT”), a company publicly traded in the Australian Stock Exchange (ASX).

GICC and HCT will set up the joint venture in Singapore. GICC will own 51% while HCT will own 49%. The announcement was made in the ASX last week.

GICC manufactures proprietary products utilized for the control and/or elimination of pathogens with an emphasis on airborne pathogens referredto as Pathogenic Bioaerosols. GICC has developed and patented products and system used in numerous and diverse industry venues such as agriculture, textiles, transportation and the poultry industry

The primary focus of the work is related to providing secure, safe, pathogen controlled indoor environments through application of the proprietary technology synergistically with the building environmental systems.

The technological breakthroughs have been tested, proven and approved and have been vetted through USA CDC, as well as USA FDA approved testing laboratories and methodologies. They have also been tested successfully in numerous foreign countries and have secured approvals there.

This technology is the answer to 24/7 all year round protection of anyfacility and occupants, visitors and guests. It helps create a safe and healthy indoor environment when infused via the Heating Ventilation and Cooling System in any large facilitywithPath-Away Anti-Pathogenic Aerosol Solution®sold as Natshield.

Through the application of our proprietary technology we can adjust and control the frequency and quantity of Path-Away Anti-Pathogenic Aerosol Solution®required to manage pathogen control across a broad spectrum of fungi, bacteria, yeasts and viruses.

After a careful assessment of specific situational needs and based on our assessments of in excess of 5,000 facilities in more than 16 countries, we can pre-program the module to provide you with the safestand most cost-effectivepathogen-controlled environment.

The joint venture will manufacture products and system in Singapore for the global market exclusive of North America.